Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028613 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT00028613: Completed Phase 1 study of Lymphoma, sponsored by Case Comprehensive Cancer Center.
NCT00028613 is a Phase 1 study of Lymphoma that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 2 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028613, a Phase 1 study of Lymphoma, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances such as radioactive iodine to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibodies in treating patients who have large cell lymphoma that has been previously treated.
Conditions Studied
Interventions
- RADIATION iodine I 131 monoclonal antibody Lym-1
Study Locations (1)
Ohio
- Ireland Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2001-03 |
| Est. Completion | 2001-10 |
| Phase | Phase 1 |
What the finished NCT00028613 record still lists
NCT00028613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which iodine I 131 monoclonal antibody Lym-1 is the first listed.
NCT00028613 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00028613 about?
NCT00028613 is a clinical study titled "Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances such as radioactive iodine to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibodies in treating patients who have large cell...
What is the current status of trial NCT00028613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2001-03. Estimated completion is 2001-10.
What conditions does trial NCT00028613 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00028613?
The interventions under investigation include: iodine I 131 monoclonal antibody Lym-1 (RADIATION).
Who is sponsoring clinical trial NCT00028613?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00028613 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00028613's enrollment target sits among peer trials
2 297th of 299 higher than 2 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia